vs
波士顿科学（BSX）与Paramount Skydance Corporation（PSKY）财务数据对比。点击上方公司名可切换其他公司
波士顿科学的季度营收约是Paramount Skydance Corporation的1.3倍（$5.2B vs $4.1B），波士顿科学净利率更高（25.7% vs -0.3%，领先26.1%），波士顿科学同比增速更快（11.6% vs -38.8%）
波士顿科学是一家美国跨国生物科技与生物医学工程企业，专注于介入医学领域医疗设备的研发生产，产品覆盖介入心内科、介入放射科、神经调控、肿瘤、泌尿、妇科、内镜、心脏及血管外科等多个专科诊疗场景。
派拉蒙天空之舞是美国跨国传媒娱乐集团，总部坐落于加利福尼亚州洛杉矶市好莱坞的派拉蒙影业园区内，旗下多家派拉蒙业务分支、子公司及核心办公会议场所均设于纽约阿斯特广场一号的原派拉蒙全球总部大楼。
BSX vs PSKY — 直观对比
营收规模更大
BSX
是对方的1.3倍
$4.1B
营收增速更快
BSX
高出50.4%
-38.8%
净利率更高
BSX
高出26.1%
-0.3%
损益表 — Q1 FY2026 vs Q3 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $5.2B | $4.1B |
| 净利润 | $1.3B | $-13.0M |
| 毛利率 | 69.5% | — |
| 营业利润率 | — | 5.9% |
| 净利率 | 25.7% | -0.3% |
| 营收同比 | 11.6% | -38.8% |
| 净利润同比 | 99.0% | -1400.0% |
| 每股收益（稀释后） | $0.90 | $-0.01 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收BSXPSKY
| Q1 26 | $5.2B | — | ||
| Q4 25 | $5.3B | — | ||
| Q3 25 | $5.1B | $4.1B | ||
| Q2 25 | $5.1B | $0 | ||
| Q1 25 | $4.7B | $0 | ||
| Q4 24 | $4.6B | — | ||
| Q3 24 | $4.2B | $6.7B | ||
| Q2 24 | $4.1B | $0 |
净利润BSXPSKY
| Q1 26 | $1.3B | — | ||
| Q4 25 | $670.0M | — | ||
| Q3 25 | $755.0M | $-13.0M | ||
| Q2 25 | $795.0M | $0 | ||
| Q1 25 | $672.0M | $0 | ||
| Q4 24 | $563.0M | — | ||
| Q3 24 | $468.0M | $1.0M | ||
| Q2 24 | $322.0M | $0 |
毛利率BSXPSKY
| Q1 26 | 69.5% | — | ||
| Q4 25 | 69.6% | — | ||
| Q3 25 | 69.9% | — | ||
| Q2 25 | 67.7% | — | ||
| Q1 25 | 68.8% | — | ||
| Q4 24 | 67.8% | — | ||
| Q3 24 | 68.8% | — | ||
| Q2 24 | 69.2% | — |
营业利润率BSXPSKY
| Q1 26 | — | — | ||
| Q4 25 | 15.6% | — | ||
| Q3 25 | 20.7% | 5.9% | ||
| Q2 25 | 16.2% | — | ||
| Q1 25 | 19.8% | — | ||
| Q4 24 | 14.8% | — | ||
| Q3 24 | 17.4% | 5.0% | ||
| Q2 24 | 12.6% | — |
净利率BSXPSKY
| Q1 26 | 25.7% | — | ||
| Q4 25 | 12.7% | — | ||
| Q3 25 | 14.9% | -0.3% | ||
| Q2 25 | 15.7% | — | ||
| Q1 25 | 14.4% | — | ||
| Q4 24 | 12.3% | — | ||
| Q3 24 | 11.1% | 0.0% | ||
| Q2 24 | 7.8% | — |
每股收益（稀释后）BSXPSKY
| Q1 26 | $0.90 | — | ||
| Q4 25 | $0.45 | — | ||
| Q3 25 | $0.51 | $-0.01 | ||
| Q2 25 | $0.53 | $0.00 | ||
| Q1 25 | $0.45 | $0.00 | ||
| Q4 24 | $0.38 | — | ||
| Q3 24 | $0.32 | $0.00 | ||
| Q2 24 | $0.22 | $0.00 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $3.3B |
| 总债务越低越好 | — | $13.3B |
| 股东权益账面价值 | — | $12.0B |
| 总资产 | — | $43.2B |
| 负债/权益比越低杠杆越低 | — | 1.11× |
8季度趋势，按日历期对齐
现金及短期投资BSXPSKY
| Q1 26 | — | — | ||
| Q4 25 | $2.0B | — | ||
| Q3 25 | $1.3B | $3.3B | ||
| Q2 25 | $534.0M | — | ||
| Q1 25 | $725.0M | — | ||
| Q4 24 | $414.0M | — | ||
| Q3 24 | $2.5B | — | ||
| Q2 24 | $2.9B | — |
总债务BSXPSKY
| Q1 26 | — | — | ||
| Q4 25 | $11.1B | — | ||
| Q3 25 | $11.1B | $13.3B | ||
| Q2 25 | $11.1B | — | ||
| Q1 25 | $10.5B | — | ||
| Q4 24 | $9.0B | — | ||
| Q3 24 | $9.2B | — | ||
| Q2 24 | $9.0B | — |
股东权益BSXPSKY
| Q1 26 | — | — | ||
| Q4 25 | $24.2B | — | ||
| Q3 25 | $23.4B | $12.0B | ||
| Q2 25 | $22.4B | $0 | ||
| Q1 25 | $22.2B | $0 | ||
| Q4 24 | $21.8B | — | ||
| Q3 24 | $20.7B | $17.1B | ||
| Q2 24 | $20.4B | $0 |
总资产BSXPSKY
| Q1 26 | — | — | ||
| Q4 25 | $43.7B | — | ||
| Q3 25 | $42.7B | $43.2B | ||
| Q2 25 | $41.6B | $0 | ||
| Q1 25 | $40.1B | $0 | ||
| Q4 24 | $39.4B | — | ||
| Q3 24 | $38.1B | — | ||
| Q2 24 | $37.1B | — |
负债/权益比BSXPSKY
| Q1 26 | — | — | ||
| Q4 25 | 0.46× | — | ||
| Q3 25 | 0.48× | 1.11× | ||
| Q2 25 | 0.50× | — | ||
| Q1 25 | 0.47× | — | ||
| Q4 24 | 0.41× | — | ||
| Q3 24 | 0.45× | — | ||
| Q2 24 | 0.44× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $268.0M |
| 自由现金流经营现金流 - 资本支出 | — | $222.0M |
| 自由现金流率自由现金流/营收 | — | 5.4% |
| 资本支出强度资本支出/营收 | — | 1.1% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流BSXPSKY
| Q1 26 | — | — | ||
| Q4 25 | $1.4B | — | ||
| Q3 25 | $1.3B | $268.0M | ||
| Q2 25 | $1.3B | $0 | ||
| Q1 25 | $541.0M | $0 | ||
| Q4 24 | $1.5B | — | ||
| Q3 24 | $1.0B | — | ||
| Q2 24 | $813.0M | $0 |
自由现金流BSXPSKY
| Q1 26 | — | — | ||
| Q4 25 | $1.0B | — | ||
| Q3 25 | $1.2B | $222.0M | ||
| Q2 25 | $1.1B | — | ||
| Q1 25 | $354.0M | — | ||
| Q4 24 | $1.2B | — | ||
| Q3 24 | $823.0M | — | ||
| Q2 24 | $658.0M | — |
自由现金流率BSXPSKY
| Q1 26 | — | — | ||
| Q4 25 | 19.2% | — | ||
| Q3 25 | 22.9% | 5.4% | ||
| Q2 25 | 22.3% | — | ||
| Q1 25 | 7.6% | — | ||
| Q4 24 | 25.8% | — | ||
| Q3 24 | 19.6% | — | ||
| Q2 24 | 16.0% | — |
资本支出强度BSXPSKY
| Q1 26 | — | — | ||
| Q4 25 | 6.6% | — | ||
| Q3 25 | 3.6% | 1.1% | ||
| Q2 25 | 3.1% | — | ||
| Q1 25 | 4.0% | — | ||
| Q4 24 | 6.1% | — | ||
| Q3 24 | 4.3% | — | ||
| Q2 24 | 3.8% | — |
现金转化率BSXPSKY
| Q1 26 | — | — | ||
| Q4 25 | 2.04× | — | ||
| Q3 25 | 1.78× | — | ||
| Q2 25 | 1.62× | — | ||
| Q1 25 | 0.81× | — | ||
| Q4 24 | 2.59× | — | ||
| Q3 24 | 2.14× | — | ||
| Q2 24 | 2.52× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
BSX
| Cardiovascular | $3.1B | 59% |
| Endoscopy | $673.0M | 13% |
| Urology | $633.0M | 12% |
| Other | $386.0M | 7% |
| Neuromodulation | $271.0M | 5% |
| LACA | $155.0M | 3% |
PSKY
| Affiliate And Subscription | $2.0B | 49% |
| Advertising | $1.3B | 31% |
| Licensing And Other | $775.0M | 19% |
| Related Party | $40.0M | 1% |
| Theatrical | $39.0M | 1% |
